|Closed||Advanced Ovarian Cancer||N/A||
Study Summary: FDG PET and Biomarkers in Treatment Response in Advanced Ovarian Cancer (AOC) or primary peritoneal cancer (Stage IIIC–IV). Goals of study are: (a) to determine the association between FDG measures of glycolysis with chemo-resistance; and (b) to determine if treatment-related changes in tumor’s FDG metabolic activity can predict treatment response, time to recurrence and disease free survival.
Recruitment Population: Recruiting previously untreated patients with biopsy/cytology proven carcinoma of the ovary or primary peritoneum; who are candidates for neoadjuvant chemotherapy.
SCCA Referral Required: Patients need to be referred to an SCCA gynecologic oncologist for consultation in order to be considered for the study.
Participant Time Requirement: 3 separate visits to University of Washington Medical Center to have a research FDG-PET imaging scan (3 hour visit). Research FDG-PET scan occurs prior to chemotherapy cycle 1; and post cycles 1 and 3.
Study Benefits: Pretreatment PET scan includes a whole body FDG-PET scan. Results will be provided to clinician.
Patients who have a new biopsy / cytology proven carcinoma of the ovary or primary peritoneum and are:
• Clinical stage IIIc–IV (by FIGO criteria) disease. Target tumor should be ≥ 1 cm.
• Candidates for neoadjuvant chemotherapy.
In addition patients must:
• Be over 18 years of age.
• Be able to give informed consent.
• Be able to lie still for the imaging procedure.
• Weigh under 350 lbs, the weight limit of the tomography table.
• Not be pregnant.
• Not have a prior ovarian cancer history, nor prior treatment or surgery for ovarian cancer.
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.